LENZ Therapeutics, Inc.
5.60%
1,575,899
1815776
52635N103
Jul 9, 2025
Jul 14, 2025, 04:50 PM
Reporting Persons (9)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | Partnership | 5.60% | 1,575,899 | 1,575,899 | 0 |
| Versant Ventures VI GP, L.P. | Partnership | 5.60% | 1,575,899 | 0 | 1,575,899 |
| Versant Ventures VI GP-GP, LLC | Other | 5.60% | 1,575,899 | 0 | 1,575,899 |
| Versant Ventures VII GP-GP, LLC | Other | 4.00% | 1,118,446 | 0 | 1,118,446 |
| Versant Venture Capital VII, L.P. | Partnership | 4.00% | 1,118,446 | 1,118,446 | 0 |
| Versant Ventures VII GP, L.P. | Partnership | 4.00% | 1,118,446 | 0 | 1,118,446 |
| Versant Vantage II, L.P. | Partnership | 3.00% | 842,162 | 842,162 | 0 |
| Versant Vantage II GP, L.P. | Partnership | 3.00% | 842,162 | 0 | 842,162 |
| Versant Vantage II GP-GP, LLC | Other | 3.00% | 842,162 | 0 | 842,162 |
Disclosure Items (2)
Common Stock, par value $0.00001 per share
LENZ Therapeutics, Inc.
201 Lomas Santa Fe Dr., Solana Beach, CA, 92075
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.
On June 27, 2025, Versant VI sold 200,000 shares of Common Stock at a weighted average price per share of $30.465 for aggregate proceeds of approximately $6,093,000.00. On July 10, 2025, Versant VI sold 191,376 shares of Common Stock at a price per share of $34.00 for aggregate proceeds of approximately $6,506,784.00.